Theravance Biopharma (TBPH) Cash from Investing Activities (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Cash from Investing Activities of $52.6 million for Q1 2026, up 71.69% year-over-year from $30.6 million in Q1 2025, and up 8844.39% quarter-over-quarter from $588000.0 in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Cash from Investing Activities for 14 consecutive years, with $52.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 71.69% year-over-year to $52.6 million; the TTM figure through Mar 2026 stood at -$83.3 million (down 421.86% YoY), while the FY2025 annual figure was -$105.3 million, down 957.08% from the prior year.
- Cash from Investing Activities grew to $52.6 million in Q1 2026 per TBPH's latest filing, from $588000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $52.6 million in Q1 2026 and bottomed at -$100.2 million in Q3 2025.
- Historically, Cash from Investing Activities has averaged -$837000.0 across 5 years, with a median of $588000.0 in 2025.
- On a YoY basis, Cash from Investing Activities climbed as much as 2416.99% in 2024 and fell as far as 82752.38% in 2024.
- Theravance Biopharma's Cash from Investing Activities stood at $39.2 million in 2022, then plunged by 101.73% to -$677000.0 in 2023, then soared by 2416.99% to $15.7 million in 2024, then slumped by 96.25% to $588000.0 in 2025, then jumped by 8844.39% to $52.6 million in 2026.
- Business Quant data shows TBPH's Cash from Investing Activities at $52.6 million in Q1 2026, $588000.0 in Q4 2025, and -$100.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | -60.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -60.40 Mn |
| Mar 31, 2026 | 52.59 Mn |
| Dec 31, 2025 | 588,000.00 |
| Sep 30, 2025 | -100.25 Mn |
| Jun 30, 2025 | -36.26 Mn |
| Mar 31, 2025 | 30.63 Mn |
| Dec 31, 2024 | 15.69 Mn |
| Sep 30, 2024 | -17.40 Mn |
| Jun 30, 2024 | -3.03 Mn |
| Mar 31, 2024 | 17.03 Mn |
| Dec 31, 2023 | -677,000.00 |
| Sep 30, 2023 | -21,000.00 |
| Jun 30, 2023 | 11.05 Mn |
| Mar 31, 2023 | -43.05 Mn |
| Dec 31, 2022 | 39.16 Mn |
| Sep 30, 2022 | 1.08 Bn |
| Jun 30, 2022 | 7.52 Mn |
| Mar 31, 2022 | 31.92 Mn |
| Dec 31, 2021 | 10.82 Mn |
| Sep 30, 2021 | -35.79 Mn |